Gossamer Bio Inc (GOSS) - Net Assets
Based on the latest financial reports, Gossamer Bio Inc (GOSS) has net assets worth $-82.33 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($208.82 Million) and total liabilities ($291.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Gossamer Bio Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-82.33 Million |
| % of Total Assets | -39.43% |
| Annual Growth Rate | N/A |
| 5-Year Change | -90.8% |
| 10-Year Change | N/A |
| Growth Volatility | 191.1 |
Gossamer Bio Inc - Net Assets Trend (2016–2024)
This chart illustrates how Gossamer Bio Inc's net assets have evolved over time, based on quarterly financial data. Also explore how large is Gossamer Bio Inc's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Gossamer Bio Inc (2016–2024)
The table below shows the annual net assets of Gossamer Bio Inc from 2016 to 2024. For live valuation and market cap data, see Gossamer Bio Inc (GOSS) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $29.49 Million | -53.02% |
| 2023-12-31 | $62.77 Million | +419.74% |
| 2022-12-31 | $12.08 Million | -90.06% |
| 2021-12-31 | $121.46 Million | -62.12% |
| 2020-12-31 | $320.68 Million | -9.02% |
| 2019-12-31 | $352.49 Million | +393.57% |
| 2018-12-31 | $-120.07 Million | -1649.77% |
| 2017-12-31 | $-6.86 Million | -5478.86% |
| 2016-12-31 | $-123.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Gossamer Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 126844500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $23.00K | 0.08% |
| Other Comprehensive Income | $1.19 Million | 4.03% |
| Other Components | $1.30 Billion | 4397.29% |
| Total Equity | $29.49 Million | 100.00% |
Gossamer Bio Inc Competitors by Market Cap
The table below lists competitors of Gossamer Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Marisa Lojas S.A
SA:AMAR3
|
$85.64 Million |
|
Alcadon Group AB
ST:ALCA
|
$85.73 Million |
|
Nuveen California Select Tax Free Income Closed Fund
NYSE:NXC
|
$85.77 Million |
|
Overseas Commerce Ltd
TA:OVRS
|
$85.78 Million |
|
SinoMedia Holding Limited
F:SJY
|
$85.64 Million |
|
The Ruby Mills Limited
NSE:RUBYMILLS
|
$85.63 Million |
|
United Bancorp Inc
NASDAQ:UBCP
|
$85.51 Million |
|
MLG OZ Ltd
AU:MLG
|
$85.51 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gossamer Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 62,769,000 to 29,492,000, a change of -33,277,000 (-53.0%).
- Net loss of 56,528,000 reduced equity.
- Share repurchases of 629,000 reduced equity.
- Other comprehensive income increased equity by 1,539,000.
- Other factors increased equity by 22,341,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-56.53 Million | -191.67% |
| Share Repurchases | $629.00K | -2.13% |
| Other Comprehensive Income | $1.54 Million | +5.22% |
| Other Changes | $22.34 Million | +75.75% |
| Total Change | $- | -53.02% |
Book Value vs Market Value Analysis
This analysis compares Gossamer Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.84x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-0.01 | $0.37 | x |
| 2017-12-31 | $-0.28 | $0.37 | x |
| 2018-12-31 | $-1.99 | $0.37 | x |
| 2019-12-31 | $6.44 | $0.37 | x |
| 2020-12-31 | $4.68 | $0.37 | x |
| 2021-12-31 | $1.62 | $0.37 | x |
| 2022-12-31 | $0.14 | $0.37 | x |
| 2023-12-31 | $0.28 | $0.37 | x |
| 2024-12-31 | $0.13 | $0.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gossamer Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -191.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -49.28%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 10.69x
- Recent ROE (-191.67%) is above the historical average (-299.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-70.70K |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.08 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-134.96 Million |
| 2019 | -51.30% | 0.00% | 0.00x | 1.21x | $-216.07 Million |
| 2020 | -75.89% | 0.00% | 0.00x | 1.68x | $-275.43 Million |
| 2021 | -192.65% | 0.00% | 0.00x | 2.83x | $-246.15 Million |
| 2022 | -1899.30% | 0.00% | 0.00x | 22.56x | $-230.59 Million |
| 2023 | -286.47% | 0.00% | 0.00x | 4.97x | $-186.09 Million |
| 2024 | -191.67% | -49.28% | 0.36x | 10.69x | $-59.48 Million |
Industry Comparison
This section compares Gossamer Bio Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gossamer Bio Inc (GOSS) | $-82.33 Million | 0.00% | N/A | $85.64 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Gossamer Bio Inc
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical tr… Read more